NCT07907640
Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in NT-proBNP
Timeframe: Baseline (Month 0) to Month 12
Secondary (10)
Change in LVEF
Change in serum creatinine
Change in eGFR
Change in serum potassium
Change in KCCQ overall summary score
Show 5 moreShow less
Cardiovascular death or first heart failure hospitalisation (composite)
Adverse events and serious adverse events
Adverse events of special interest
Change in Dietary Diversity Score (DDS)
Association between DDS and clinical outcomes
Arms and interventions
Savagen (sacubitril/valsartan)
Patients with HFrEF starting Savagen as part of routine care. Initiation and titration by the treating physician per standard institutional protocol; visits at Month 0, 6 and 12.
Drugs: Savagen (sacubitril/valsartan)
Sites
2 sites in 1 country